COLORADO SPRINGS, Colo., Dec. 28, 2016 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq: SPNC ) today announced that its management will be presenting at the 35th Annual J.P. Morgan Healthcare Conference on January 11, 2017 in San Francisco, California. The presentation is scheduled for 3:30 pm PT. A live audio webcast of the presentation will be available on the Investor Relations portion of Spectranetics’ website at http://www.spectranetics.com/investor-relatio...or-events/ .
About Spectranetics The Spectranetics Corporation develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are available in over 65 countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads. The Company's Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee, the AngioSculpt scoring balloon used in both peripheral and coronary procedures, and the Stellarex drug-coated balloon peripheral angioplasty platform, which received European CE mark approval in December 2014. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets aspiration and cardiac laser catheters to treat blockages in the heart. The Lead Management (LM) product line includes excimer laser sheaths, dilator sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads. For more information, visit www.spectranetics.com .
Investor Relations Contacts Zach Stassen Investor.relations@spnc.com (719) 447-2292 Michaella Gallina Investor.relations@spnc.com (719) 447-2417
